NCI PATTERNS OF CARE (POC)/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2019 (URINARY BLADDER CANCER AND KIDNEY CANCER)

2021财年NCI POC研究的主要目标是：1)描述推荐的生物标记物测试的使用，应与治疗医生/医生办公室工作人员核实或使用统一的医疗记录(记录与所有住院和门诊记录在一个文件中)和2)描述靶向治疗的使用，应与治疗医生/医生办公室工作人员或使用统一的医疗记录(记录与所有住院和门诊记录在一个文件中)。其他目标是：3)描述辅助治疗的使用，应与治疗医生/医生办公室工作人员核实，或使用统一的医疗记录(所有住院和门诊记录记录在一个文件中)；4)描述不同社区的实践模式；5)比较治疗模式(手术、放射治疗、全身治疗(化疗、免疫治疗、激素治疗、靶向治疗)和其他辅助治疗)随时间和年龄、性别、种族/民族和保险状况的变化；6)描述合并症和合并症对治疗的影响；7)描述医院的特点(即盈利与非盈利、教学与非教学、床位大小等)；8)描述诊断测试的使用，并按人口统计变量和地理区域比较它们的使用；9)描述多学科护理和患者导航的病历文件；10)评估癌症复发的发生率；11)收集由于药物短缺而导致的癌症治疗模式变化的信息。

The primary objectives of the Fiscal Year 2021 NCI POC Study are to: 1) describe the use of recommended biomarker tests which shall be verified with the treating physician/physician office staff or with a unified medical record (record with all inpatient and outpatient records in a single file) and 2) describe the use of targeted therapy which shall be verified with the treating physician/physician office staff or with a unified medical record (record with all inpatient and outpatient records in a single file). Other objectives are to: 3) describe the use of adjuvant therapy, which shall be verified with the treating physician/physician office staff or with a unified medical record (record with all inpatient and outpatient records in a single file); 4) characterize the practice patterns in different communities; 5) compare the patterns of treatment (surgery, radiation therapy, systemic therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy), and other adjuvant therapy) over time and by age, sex, race/ethnicity, and insurance status; 6) describe comorbidities and the effect of co-morbid conditions on treatment; 7) describe treatment by hospital characteristics (i.e., for profit vs. not for profit, teaching vs. non-teaching, bed size, etc.); 8) describe the use of diagnostic tests and compare their use by demographic variables and geographic region; 9) describe the medical record documentation of multidisciplinary care and patient navigation; 10) assess the incidence of cancer recurrence; and 11) collect information on changes in cancer treatment patterns due to medication shortages.